Peptide therapeutics are acclaimed as a promising addition to the pharmaceutical arena, and they continue to attract interest due to their high potency, bioavailability, and fewer concerns with toxicity, drug to drug cross-reactions, and tissue accumulation.1,2 Although poor drug delivery and low in vivo stability are still issues to be addressed, peptides look poised to play an important role in the treatment of diseases ranging from Alzheimer's disease to cancer.2,3 The huge biodiversity offered by venom peptides, specially conotoxins isolated from the venom of predatory marine snails, holds enormous promise for the development of peptide-based drugs.